In the early days of April 2021, Europe's foremost drug regulator found itself speaking in two voices at once — one belonging to a senior official who told an Italian newspaper that a link between the AstraZeneca vaccine and rare blood clots was now clear, and another belonging to the institution itself, which swiftly denied any final conclusion had been reached. The European Medicines Agency, tasked with guarding public trust in medicines across a continent mid-pandemic, had inadvertently exposed the fault line between what scientists privately believe and what institutions are prepared to sa
EMA clarifies stance on AstraZeneca vaccine blood clot link amid conflicting signals
Rare but serious blood clotting events reported in small number of vaccine recipients across Europe.
We can say it now, it is clear there is a link
Mark
Why did the EMA's head of vaccines say something the agency immediately denied?
Mimi
He wasn't lying—he was expressing what he believed the evidence showed. But the agency wasn't ready to make that official. There's a difference between what one expert thinks and what an institution is prepared to stake its credibility on.
Mark
So the investigation wasn't finished?
Mimi
No. They were still analyzing the data. Cavaleri may have seen enough to form an opinion, but the formal review process required more time, more scrutiny, more consensus among the committee.
Mark
What was at stake if they got it wrong?
Mimi
Everything. If they said there was a link and there wasn't, they'd undermine confidence in vaccines when people needed them most. If they said there wasn't a link and there was, they'd expose millions to harm. Either way, trust in regulators would suffer.
Mark
Why did Australia care what the EMA concluded?
Mimi
Because other countries look to major regulators for guidance. If Europe's drug agency found a real problem, Australia would have to reckon with it. If Europe cleared the vaccine, that would carry weight too.
Mark
Did anyone know the actual risk at that point?
Mimi
Not precisely. The clotting events were real but rare. The question was whether the vaccine caused them or whether they were coincidental. That's what the investigation was trying to determine.
Il Polso
- A senior EMA vaccines official publicly declared a causal link between the AstraZeneca jab and rare blood clotting events, only for his own agency to contradict him within hours.
- Over a dozen European nations had already suspended the vaccine's use, and the public contradiction between regulator and institution deepened an anxiety already weeks in the making.
- The gap between what a senior scientist believed and what the agency was willing to formally state created a crisis of credibility at the worst possible moment in the vaccination campaign.
- Australia and other nations were monitoring the EMA's review closely, with some reportedly reconsidering export arrangements — meaning the fallout threatened to extend well beyond Europe.
- The EMA's formal findings, expected by Thursday, carried the weight of resolving not just a scientific question but a continent-wide test of confidence in immunization itself.
In the early days of April 2021, Europe's foremost drug regulator found itself speaking in two voices at once — one belonging to a senior official who told an Italian newspaper that a link between the AstraZeneca vaccine and rare blood clots was now clear, and another belonging to the institution itself, which swiftly denied any final conclusion had been reached. The European Medicines Agency, tasked with guarding public trust in medicines across a continent mid-pandemic, had inadvertently exposed the fault line between what scientists privately believe and what institutions are prepared to say aloud. With formal findings expected within days, millions of Europeans — and governments watching from beyond the continent — were left to sit with uncertainty at precisely the moment certainty was most needed.
On a Tuesday morning in early April 2021, Marco Cavaleri — the European Medicines Agency's head of vaccines — told an Italian newspaper what many inside the agency may already have believed: that a link between the AstraZeneca vaccine and rare blood clotting events was now evident. "We can say it now," he said, though he admitted the underlying mechanism remained unclear. Within hours, the EMA issued a formal denial, stating its review was still ongoing and that official findings would follow by Wednesday or Thursday. The contradiction was immediate and damaging.
The episode crystallized a tension that had been building for weeks. Reports of rare but serious clotting events among AstraZeneca recipients had prompted more than a dozen European countries to pause the vaccine's use while regulators investigated. The incidents were uncommon — affecting a small fraction of millions vaccinated — but real enough to force governments into an uncomfortable calculation: the documented dangers of COVID-19 weighed against the poorly understood risks of a vaccine already being deployed at scale.
Cavaleri's phrasing implied a threshold had been crossed internally. Yet the agency's public posture remained cautious, committed to process and pending analysis. The space between those two positions — what a senior regulator believed and what the institution would formally declare — generated precisely the kind of confusion that erodes public trust. Millions of Europeans, vaccinated or awaiting vaccination, were watching for a clear answer from the body whose purpose was to provide one.
The stakes extended beyond Europe. Australia had reportedly asked the EMA to clarify its position, and some governments were reconsidering export arrangements pending the outcome. Whatever the EMA concluded would ripple outward, shaping rollout decisions and public confidence across multiple continents. Deeper still, the unresolved questions — why some recipients developed clots and others did not, what made certain individuals vulnerable — mattered not just scientifically but practically. If the risk could be identified and managed, the vaccine might still serve its purpose. If not, the entire calculus would shift. Europe waited, suspended between one official's candor and an institution's caution, for regulators to finally speak with a single voice.
The European Medicines Agency found itself in an awkward position on Tuesday, forced to walk back remarks from one of its own senior officials about the Oxford-AstraZeneca vaccine and blood clots. Marco Cavaleri, the agency's head of vaccines, had told Italy's Il Messaggero newspaper that morning that a connection between the shot and rare clotting events was evident. "We can say it now, it is clear there is a link with the vaccine," he said, though he acknowledged the mechanism remained unclear. Within hours, the EMA issued a formal statement to Agence France-Presse denying it had reached any such conclusion. The agency said its review was still underway and that it expected to publish its findings by Wednesday or Thursday.
The contradiction laid bare the tension running through Europe's vaccine rollout in early April 2021. For weeks, reports of rare but serious blood clotting events had circulated among recipients of the AstraZeneca jab, prompting more than a dozen European countries to pause its use while regulators investigated. The incidents were uncommon—affecting a small fraction of the millions vaccinated—but they were real enough to trigger alarm and uncertainty. Governments and health authorities faced a difficult calculus: the known risks of COVID-19 against the unknown or poorly understood risks of a vaccine that had been authorized and was being deployed at scale.
Cavaleri's comments suggested the EMA's internal assessment had already tilted toward acknowledging a causal relationship. His phrasing—"we can say it now"—implied a threshold had been crossed, a conclusion reached. Yet the agency's official response suggested something more cautious: ongoing review, pending analysis, findings to come. The gap between what a senior regulator believed and what the institution was prepared to state publicly created confusion precisely when clarity was needed most. Millions of Europeans were watching to see whether the vaccine they had received or were about to receive was safe. Conflicting signals from the very body tasked with answering that question only deepened the anxiety.
The timing mattered. The EMA's formal announcement was imminent—a matter of days. That statement would carry weight far beyond Europe. Other countries, including Australia, were watching the European investigation closely. Australia's government had reportedly asked the EMA to clarify its position, and some reports suggested Australian authorities were considering whether to withdraw pending export permit applications for the vaccine. The EMA's decision would ripple outward, shaping vaccination campaigns and public confidence in immunization efforts across multiple continents.
What remained unresolved was the nature of the link itself. Even if a causal connection existed, the mechanism was not yet understood. Why did some recipients develop clots and others did not? What made certain individuals vulnerable? These questions mattered not just for scientific completeness but for practical guidance: if the risk could be identified and mitigated, the vaccine might still have a role. If it could not, the calculus changed entirely. The EMA's statement promised answers within days. Until then, Europe remained in a state of suspended judgment, waiting for regulators to speak with one voice.
Citazioni salienti
We can say it now, it is clear there is a link with the vaccine. But we still do not know what causes this reaction.— Marco Cavaleri, EMA head of vaccines, to Il Messaggero
The EMA has not yet reached a conclusion and the review is currently ongoing.— European Medicines Agency statement to Agence France-Presse
Vuoi la storia completa?
Leggi l'originale su The Guardian ↗
Health & Medicine